COVID-19: Mayo Clinic is committed to taking care of our patients, learners and staff as we address the COVID-19 situation. Learn more about COVID-19 online education, resources, and live course cancellations through December 31, 2020.
Clovis Oncology - Exhibitor

 

www.clovisoncology.com

Contact Information:

Michael Carr
mcarr@clovisoncology.com
612-308-6317

Nate McClellan
nmcclellan@clovisoncology.com
320-224-7453

Virtual Exhibit Hall Home

Three Rubraca (Rucaparib) indications:

  1. Rubraca is indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic) associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane- based chemotherapy.
  2. Rubraca tablets are indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
  3. Rubraca is indicated for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic) associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies. Select patients for therapy based on an FDA- approved companion diagnostic for Rubraca.

HCP Approval Announcement 

Beyond BRCA Rubraca 

Maintenance Matters Rubraca